Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Paltusotine is an oral selective nonpeptide somatostatin receptor type 2 agonists designed for the treatment of acromegaly and neuroendocrine tumors. CRN04777 is Co.'s investigational, oral, nonpeptide somatostatin receptor type 5 agonist designed for the treatment of congenital hyperinsulinism. CRN04894 is Co.'s investigational, oral, nonpeptide product candidate designed to antagonize adrenocorticotrophic hormone, or ACTH, intended for the treatment of diseases caused by excess ACTH. The CRNX stock yearly return is shown above.
The yearly return on the CRNX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CRNX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|